Subscribe Us

header ads

Recents

header ads

US Generic Drugs Market Size At Around US$ 721.54 Bn In 2030

The US generic drugs market would grow at a CAGR of 5.18% over the predicted time frame. The market is expected to increase in value from US$ 435.54  Bn in 2022 to US$ 721.54 Bn in 2030.

US Generic Drug Market Size 2023 To 2032

The on US generic drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2486

A recent report provides crucial insights along with application based and forecast information in the Global US generic drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the US generic drugs market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global US generic drugs market are included as given below:

US generic drugs Market Key Players

  • Pfizer Inc
  • Teva Pharmaceuticals USA, Inc
  • Aurobindo Pharma USA, Inc
  • Sun pharma Inc
  • Abbott Laboratories Inc
  • Lupin Pharmaceuticals, Inc
  • Mylan
  • Dr. Reddy’s
  • Novartis
    • Eli Lilly company 

Market Segments

By Type

  • Pure Generic Drugs
  • Branded Generic Drugs

By Route of Administration

  • Oral
  • Topical
  • Parental
  • others

By Therapeutic Application 

  • Cardiovascular
  • Central nervous system (CNS)
  • Dermatology
  • Oncology
  • Respiratory
  • Others

By Distribution Channels

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

Report Objectives

  • To define, describe, and forecast the global US generic drugs market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the US generic drugs market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Generic Drug Market 

5.1. COVID-19 Landscape: US Generic Drug Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global US Generic Drug Market, By Type

8.1. US Generic Drug Market, by Type, 2022-2032

8.1.1. Pure Generic Drugs

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Branded Generic Drugs

8.1.2.1. Market Revenue and Forecast (2022-2032)

Chapter 9. Global US Generic Drug Market, By Route of Administration

9.1. US Generic Drug Market, by Route of Administration, 2022-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2022-2032)

9.1.3. Parental

9.1.3.1. Market Revenue and Forecast (2022-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 10. Global US Generic Drug Market, By Therapeutic Application 

10.1. US Generic Drug Market, by Therapeutic Application, 2022-2032

10.1.1. Cardiovascular

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Central nervous system (CNS)

10.1.2.1. Market Revenue and Forecast (2022-2032)

10.1.3. Dermatology

10.1.3.1. Market Revenue and Forecast (2022-2032)

10.1.4. Oncology

10.1.4.1. Market Revenue and Forecast (2022-2032)

10.1.5. Respiratory

10.1.5.1. Market Revenue and Forecast (2022-2032)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2022-2032)

Chapter 11. Global US Generic Drug Market, By Distribution Channels 

11.1. US Generic Drug Market, by Distribution Channels, 2022-2032

11.1.1. Retail Pharmacies

11.1.1.1. Market Revenue and Forecast (2022-2032)

11.1.2. Online Pharmacies

11.1.2.1. Market Revenue and Forecast (2022-2032)

11.1.3. Hospital Pharmacies

11.1.3.1. Market Revenue and Forecast (2022-2032)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 12. Global US Generic Drug Market, Regional Estimates and Trend Forecast

12.1. U.S.

12.1.1. Market Revenue and Forecast, by Type (2022-2032)

12.1.2. Market Revenue and Forecast, by Route of Administration (2022-2032)

12.1.3. Market Revenue and Forecast, by Therapeutic Application (2022-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channels (2022-2032)

Chapter 13. Company Profiles

13.1. Pfizer Inc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Teva Pharmaceuticals USA, Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Aurobindo Pharma USA, Inc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sun pharma Inc

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Abbott Laboratories Inc

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lupin Pharmaceuticals, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Mylan

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Dr. Reddy’s

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Novartis

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Eli Lilly company

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments